Kypha provides an innovative testing platform for precision monitoring of immune system activity to improve patient care and advance immune-targeted drug development. Its platform can enable complement testing at scale from home health to clinical laboratories, supporting precision immune monitoring as standard of care in a growing multi-billion dollar complement drug and immunotherapy marketplace. The company recently acquired Biosensia and plans to complete integration and expand the manufacturing capacity of Biosensia's ISO 13485-certified facilities in Dublin, Ireland. Biosensia operates as a Kypha wholly-owned subsidiary and develops, manufactures, and commercializes multi-analyte quantitative and qualitative assays on a low-complexity, CLIA-waived testing platform, and also offers contract assay development and manufacturing services. Kypha intends to use new funds to support commercial launch of additional Kypha tests and to expand partnerships with pharmaceutical companies advancing therapies targeting complement. The company is led by CEO Chad Stiening and is based in St Louis, MO. Kypha makes a point-of-care test that uses a single drop of blood to assign a numeric value indicating inflammation within minutes, operating similarly to a diabetes test. The core product is designed to give clinicians rapid, actionable information at the bedside. The company positions the test to help physicians make more effective decisions for diseases where inflammation monitoring is critical, such as lupus. Kypha raised a $2.1 million debt offering to further its work in managing inflammation. Prior to this raise, the company had secured $6 million for development plus $1.5 million in grants. Investors in the company have included BioGenerator, Arsenal Capital Management, Serra Ventures, Saint Louis University’s Billiken Angels Network, St. Louis Arch Angels, and Holton Capital Group.

Total raised

$6M

Funding rounds

2

Latest round

Series A

Latest activity

Dec 2018